Current Report Filing (8-k)

Date : 04/21/2017 @ 1:41PM
Source : Edgar (US Regulatory)
Stock : Lion Biotechnologies, Inc. (MM) (LBIO)
Quote : 7.05  -0.15 (-2.08%) @ 4:34PM

Current Report Filing (8-k)

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): April 20, 2017

 

LION BIOTECHNOLOGIES, INC.

 

(Exact Name of Registrant as Specified in Charter)

 

Nevada
(State of Incorporation)
 
001-36860   75-3254381
Commission File Number   (I.R.S. Employer Identification No.)
     
999 Skyway Road, Suite 150    
San Carlos, California   94070
(Address of Principal Executive Offices)   (Zip Code)
     
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 

 

Item 7.01. Regulation FD Disclosure.

 

Lion Biotechnologies, Inc. (the “Company”) from time to time makes presentations to analysts, current stockholders and others. A copy of the Company’s presentation is furnished as Exhibit 99.1 to this current report on Form 8-K and incorporated under this Item 7.01 by reference.

 

The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference to any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

 

Item 9.01 Financial Statements And Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Lion Biotechnologies, Inc., Corporate Presentation.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 20, 2017 LION BIOTECHNOLOGIES, INC.  
       
       
  By:   /s/ MARIA FARDIS  
    Maria Fardis, Chief Executive Officer       

 

 

 

Lion Biotechnologies, Inc. (NASDAQ:LBIO)
Historical Stock Chart

1 Year : From Apr 2016 to Apr 2017

Click Here for more Lion Biotechnologies, Inc. Charts.

Lion Biotechnologies, Inc. (NASDAQ:LBIO)
Intraday Stock Chart

Today : Friday 28 April 2017

Click Here for more Lion Biotechnologies, Inc. Charts.



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.